ME03090B - Pirazolamidni spoj i njegova upotreba u medicini - Google Patents

Pirazolamidni spoj i njegova upotreba u medicini

Info

Publication number
ME03090B
ME03090B MEP-2018-110A MEP2018110A ME03090B ME 03090 B ME03090 B ME 03090B ME P2018110 A MEP2018110 A ME P2018110A ME 03090 B ME03090 B ME 03090B
Authority
ME
Montenegro
Prior art keywords
pirazolamide
medicine
compound
pirazolamide compound
Prior art date
Application number
MEP-2018-110A
Other languages
German (de)
English (en)
French (fr)
Inventor
Takahisa Motomura
Gakujun Shomi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03090(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of ME03090B publication Critical patent/ME03090B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
MEP-2018-110A 2013-03-15 2018-03-14 Pirazolamidni spoj i njegova upotreba u medicini ME03090B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361791164P 2013-03-15 2013-03-15
JP2013053195 2013-03-15
JP2013127318 2013-06-18
EP14763385.3A EP2975028B1 (en) 2013-03-15 2014-03-14 Pyrazole-amide compound and medicinal uses therefor
PCT/JP2014/056825 WO2014142290A1 (ja) 2013-03-15 2014-03-14 ピラゾール－アミド化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
ME03090B true ME03090B (me) 2019-01-20

Family

ID=51536938

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-110A ME03090B (me) 2013-03-15 2018-03-14 Pirazolamidni spoj i njegova upotreba u medicini

Country Status (31)

Country Link
US (4) US9040717B2 (me)
EP (3) EP2975028B1 (me)
JP (6) JP6208603B2 (me)
KR (1) KR102226096B1 (me)
CN (1) CN105051015B (me)
AU (1) AU2014230569B2 (me)
BR (1) BR112015022077A2 (me)
CA (1) CA2904985C (me)
CL (1) CL2015002608A1 (me)
CY (1) CY1120173T1 (me)
DK (1) DK2975028T3 (me)
ES (1) ES2663789T3 (me)
HR (1) HRP20180635T1 (me)
HU (1) HUE036672T2 (me)
IL (1) IL241355B (me)
LT (1) LT2975028T (me)
ME (1) ME03090B (me)
MX (1) MX373716B (me)
MY (1) MY182884A (me)
NO (1) NO2975028T3 (me)
PE (1) PE20151595A1 (me)
PH (1) PH12015501993A1 (me)
PL (1) PL2975028T3 (me)
PT (1) PT2975028T (me)
RS (1) RS57188B1 (me)
RU (1) RU2664532C2 (me)
SG (1) SG11201507327TA (me)
SI (1) SI2975028T1 (me)
SM (1) SMT201800196T1 (me)
TW (1) TWI633885B (me)
WO (1) WO2014142290A1 (me)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
MY182884A (en) * 2013-03-15 2021-02-05 Japan Tobacco Inc Pyrazole-amide compound and medicinal uses therefor
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN114716377A (zh) * 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US10800784B2 (en) * 2018-02-01 2020-10-13 Japan Tobacco Inc. Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof
US20220362215A1 (en) * 2018-09-11 2022-11-17 Japan Tobacco Inc. Therapeutic or prophylactic agent for chronic kidney disease containing pyrazole-amide compound
EP3936127B1 (en) 2019-03-04 2025-04-30 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
PL4116301T3 (pl) * 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne
CN117897382A (zh) * 2021-09-01 2024-04-16 日本烟草产业株式会社 含氮三环化合物及其药物用途
KR102769218B1 (ko) * 2022-09-28 2025-02-24 주식회사 제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도
WO2025079741A1 (ko) * 2023-10-10 2025-04-17 경북대학교 산학협력단 항노화용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) * 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2005080322A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. フルオレン誘導体
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
RU2007147844A (ru) * 2005-05-23 2009-06-27 Джапан Тобакко Инк. (Jp) Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
FR2936173B1 (fr) * 2008-09-22 2012-09-21 Snecma Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
EP2423176A4 (en) * 2009-04-22 2012-11-07 Astellas Pharma Inc CARBOXYLIC ACID COMPOUND
MY182884A (en) * 2013-03-15 2021-02-05 Japan Tobacco Inc Pyrazole-amide compound and medicinal uses therefor
WO2014142291A1 (ja) * 2013-03-15 2014-09-18 日本たばこ産業株式会社 フルオレン化合物の水和物、およびその結晶
TW201536748A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 茀－醯胺化合物及其醫藥用途
JP2015028009A (ja) 2013-07-01 2015-02-12 日本たばこ産業株式会社 ピラゾール−アルコール化合物およびその医薬用途

Also Published As

Publication number Publication date
RU2664532C2 (ru) 2018-08-20
CN105051015B (zh) 2018-09-25
JP2019194197A (ja) 2019-11-07
IL241355B (en) 2019-03-31
CL2015002608A1 (es) 2016-03-04
IL241355A0 (en) 2015-11-30
HUE036672T2 (hu) 2018-07-30
AU2014230569A1 (en) 2015-10-08
JP2015024984A (ja) 2015-02-05
EP3805205A1 (en) 2021-04-14
SMT201800196T1 (it) 2018-05-02
HRP20180635T1 (hr) 2018-06-01
EP2975028A1 (en) 2016-01-20
AU2014230569B2 (en) 2017-11-23
PL2975028T3 (pl) 2018-10-31
LT2975028T (lt) 2018-04-10
MY182884A (en) 2021-02-05
JP2020189855A (ja) 2020-11-26
US20180256547A1 (en) 2018-09-13
MX2015012743A (es) 2016-02-19
RS57188B1 (sr) 2018-07-31
JP2022000453A (ja) 2022-01-04
TW201501711A (zh) 2015-01-16
SG11201507327TA (en) 2015-10-29
EP2975028B1 (en) 2018-02-21
RU2015144182A (ru) 2017-04-24
NO2975028T3 (me) 2018-07-21
PH12015501993B1 (en) 2016-01-11
US20200163937A1 (en) 2020-05-28
PH12015501993A1 (en) 2016-01-11
EP3348545A1 (en) 2018-07-18
MX373716B (es) 2020-05-08
CN105051015A (zh) 2015-11-11
DK2975028T3 (en) 2018-03-12
US20160074364A1 (en) 2016-03-17
CY1120173T1 (el) 2018-12-12
PT2975028T (pt) 2018-03-29
CA2904985C (en) 2021-07-20
US20140296315A1 (en) 2014-10-02
PE20151595A1 (es) 2015-11-24
RU2015144182A3 (me) 2018-03-06
JP6208603B2 (ja) 2017-10-04
BR112015022077A2 (pt) 2017-07-18
CA2904985A1 (en) 2014-09-18
TWI633885B (zh) 2018-09-01
KR20150131221A (ko) 2015-11-24
EP2975028A4 (en) 2016-08-17
SI2975028T1 (en) 2018-07-31
KR102226096B1 (ko) 2021-03-09
WO2014142290A1 (ja) 2014-09-18
ES2663789T3 (es) 2018-04-17
JP2018021061A (ja) 2018-02-08
US9040717B2 (en) 2015-05-26
HK1215808A1 (en) 2016-09-15
JP2018188449A (ja) 2018-11-29

Similar Documents

Publication Publication Date Title
FIC20260008I1 (fi) tsuranoloni ja sen farmaseuttisesti hyväksyttävät suolat
FIC20260001I1 (fi) Oletsarseeni ja sen farmaseuttisesti hyväksyttävät suolat
ME03090B (me) Pirazolamidni spoj i njegova upotreba u medicini
NO2021012I1 (no) avapritinib and pharmaceutically acceptable salts thereof
HUE037275T2 (hu) Gyógyszer-kombináció
EP2953116A4 (en) Display apparatus and device
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
BR302013005965S1 (pt) Configuração aplicada em otomana
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
PL3064491T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
BR112016004943A2 (pt) aparelho médico e uso
DK3590499T3 (da) Inhalerbare lægemidler
IL244751A0 (en) Cyclic thianouracil-carboxamides and their use
EP3041028A4 (en) LAMINATE AND APPLICATION THEREOF
BR302013005862S1 (pt) Configuração aplicada em coador
FI20135799L (fi) Kaivon yhteydessä käytettävä turvalaite
BR302014001901S1 (pt) Configuração aplicada em organizador
FR3007291B1 (fr) Composition cicatrisante et utlisation
BR112015024661A2 (pt) silo e silo elevado
PL2769662T3 (pl) Zmywarka do naczyń i sposób obsługi zmywarki do naczyń
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
HRP20181735T1 (hr) Liposom za topikalnu primjenu i njegova uporaba
DE112014002244A5 (de) Infusionslösung
FR3013565B1 (fr) Bagage a peson